These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 26038780)
1. [Therapeutic option after failure of first-line chemotherapy]. Pneumologie; 2015 Apr; 69(4):245. PubMed ID: 26038780 [No Abstract] [Full Text] [Related]
2. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281 [TBL] [Abstract][Full Text] [Related]
7. Intraventricular chemotherapy for leptomeningeal carcinomatosis from lung cancer: a feasible and beneficial treatment option? Christoph DC; Reckamp KL J Thorac Oncol; 2013 May; 8(5):523-4. PubMed ID: 23584292 [No Abstract] [Full Text] [Related]
8. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy. Lin CM; Chen CH; Chang JW; Tsao TC Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958 [TBL] [Abstract][Full Text] [Related]
10. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer. Reck M; Heigener D; Reinmuth N Expert Rev Clin Pharmacol; 2014 Sep; 7(5):579-90. PubMed ID: 25119062 [TBL] [Abstract][Full Text] [Related]
11. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Popat S; Mellemgaard A; Fahrbach K; Martin A; Rizzo M; Kaiser R; Griebsch I; Reck M Future Oncol; 2015; 11(3):409-20. PubMed ID: 25478720 [TBL] [Abstract][Full Text] [Related]
12. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311 [TBL] [Abstract][Full Text] [Related]
14. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change? Diasio RB N Engl J Med; 2004 Apr; 350(17):1777-9. PubMed ID: 15103005 [No Abstract] [Full Text] [Related]
18. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. Dhruva N; Socinski MA J Clin Oncol; 2009 Aug; 27(22):e31-2. PubMed ID: 19487379 [No Abstract] [Full Text] [Related]
19. Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study). Morgensztern D; Herbst RS J Clin Oncol; 2012 Aug; 30(23):2805-8. PubMed ID: 22753916 [No Abstract] [Full Text] [Related]
20. [Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?]. Greillier L; Barlesi F Rev Mal Respir; 2012 Jan; 29(1):4-6. PubMed ID: 22240212 [No Abstract] [Full Text] [Related] [Next] [New Search]